Table 2:
Ongoing Clinical Trials
| Category of Therapy | Trial Number (clinicaltrials.gov) – Name/Description |
|---|---|
| Oncolytic Viruses |
NCT02626000 (MASTERKEY232 / KEYNOTE-137) - Talimogene
Laherparepvec + Pembro in recurrent/metastatic
HNSCC NCT00625456 - Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors NCT03740256 - Attenuated Vaccinia Virus (GL-ONC1) in combination with cisplatin and radiation therapy in locoregionally advanced HNSCC |
| Cancer Vaccines |
NCT03633110 - Safety, Tolerability, Immunogenicity, and
Antitumor Activity of GEN-009 Adjuvanted
Vaccine NCT03548467 - Safety, Feasibility, Efficacy of Multiple Dosing With VB10.NEO Immunotherapy in Patients With LA or metastatic solid tumors NCT02432963 - p53MVA vaccine (modified Vaccinia Virus Ankara Vaccine expressing p53) + Pembro in solid tumors after failed prior therapy NCT02955290 - Human EGF-rP64K/montanide ISA 51 vaccine (CIMAvax) + nivolumab in advanced HNSCC and non-small cell lung cancer NCT02544880 - PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC NCT03946358 - Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) (VolATIL) NCT00021424 - Recombinant fowlpox-TRICOM vaccine therapy in Stage IV HNSCC NCT03418480 - Phase I/II vaccine dose escalation study with intradermal injections of HPV Anti-CD40 RNA Vaccine (HARE-40) in patients with advanced HPV 16+ cancers NCT03260023 - TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies (including OPSCC) NCT00257738 - 0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck NCT02002182 - DXS 11–001 Vaccination Prior to Robotic Surgery, HPV-Positive OPSCC |
| Immunomodulatory |
NCT03689192 - Arginase-1 Peptide Vaccine in Patients
With Metastatic Solid Tumors NCT02752074 (Keynote-252 / ECHO-301) - A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma NCT02740270 - Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas NCT02274155 - Anti-OX40 Antibody in Head and Neck Cancer Patients |
| T-cell Therapy |
NCT03578406 - HPV-E6-Specific Anti-PD1 TCR-T Cells in
the Treatment of HPV-Positive NHSCC or Cervical Cancer |
HNSCC – Head and Neck Squamous Cell Carcinoma, OPSCC – Oropharynx Squamous Cell Carcinoma, LA – locally Advanced